GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » PetVivo Holdings Inc (OTCPK:PETV) » Definitions » Long-Term Capital Lease Obligation

PetVivo Holdings (PetVivo Holdings) Long-Term Capital Lease Obligation : $1.06 Mil (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is PetVivo Holdings Long-Term Capital Lease Obligation?

PetVivo Holdings's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.06 Mil.

PetVivo Holdings's quarterly Long-Term Capital Lease Obligation declined from Jun. 2023 ($1.22 Mil) to Sep. 2023 ($1.14 Mil) and declined from Sep. 2023 ($1.14 Mil) to Dec. 2023 ($1.06 Mil).

PetVivo Holdings's annual Long-Term Capital Lease Obligation increased from Mar. 2021 ($0.13 Mil) to Mar. 2022 ($0.24 Mil) but then stayed the same from Mar. 2022 ($0.24 Mil) to Mar. 2023 ($0.24 Mil).


PetVivo Holdings Long-Term Capital Lease Obligation Historical Data

The historical data trend for PetVivo Holdings's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PetVivo Holdings Long-Term Capital Lease Obligation Chart

PetVivo Holdings Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Long-Term Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.12 0.13 0.24 0.24

PetVivo Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Long-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.24 1.22 1.14 1.06

PetVivo Holdings  (OTCPK:PETV) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

PetVivo Holdings Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of PetVivo Holdings's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


PetVivo Holdings (PetVivo Holdings) Business Description

Traded in Other Exchanges
N/A
Address
5251 Edina Industrial Boulevard, Edina, MN, USA, 55439
PetVivo Holdings Inc is an emerging biomedical device company. The group is focused on the manufacturing, commercialization, and licensing of medical devices and therapeutics for companion animals. A key strategy of the company is to leverage human therapies for the treatment of companion animals cost-effectively and in a timely manner. The accelerated timeline to revenues for veterinary medical devices is a key component of this strategy, which enter the market much earlier than pharmaceuticals and biologics. The product pipeline includes approximately seventeen products intended to treat animals and people. Its patent protection extends to biomaterials, products, production processes, and methods of use provided by the company's portfolio of nineteen patents.
Executives
James Rudolph Martin director POBOX 53988, IRVINE CA 92619
A.l. Sarroff Fund, Llc 10 percent owner 43 MEADOW WOODS ROAD, GREAT NECK NY 11020
John Spencer Breithaupt director 3041 W. PASADENA DR., BOISE ID 83705
Robert J Costantino director 5805 SEPULVEDA BLVD., SUITE 801, SHERMAN OAKS CA 91411
Joseph William Jasper director 201 SOUTH 11TH STREET, UNIT 1030, MINNEAPOLIS MN 55403
John Lai director, 10 percent owner, officer: CEO 12100 SINGLETREE LANE, SUITE 186, EDEN PRAIRIE MN 55344
Robert James Rudelius director 6913 ARBOR LANE, MCCLEAN VA 22101
Leslie Anne Coolidge director 345 OLD SUTTON ROAD, BARRINGTON HILLS IL 60010
Robert J. Folkes officer: Chief Financial Officer 1331 TYLER STREET NE, SUITE 200, MINNEAPOLIS MN 55413
Scott Mitchell Johnson director 475 LAKESHORE UNIT #32, INCLINE VILLAGE NV 89451
James Joseph Martin director 4400 BISCAYNE BLVD, SUITE # 670, MIAMI FL 33157
Gregory D Cash director
John Michael Carruth officer: Acting Chief Financial Officer 4923 RIVER WOOD DR., SAVAGE MN 55439
Sherry Grisewood director 377 FAIRMOUNT ROAD, CALIFON NJ 07830
David Don Deming director 16200 45TH STREET SOUTH, AFTON MN 55001